{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:33:31Z","timestamp":1793374411898,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.anai.2020.08.016","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T16:56:43Z","timestamp":1597683403000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"title":["New treatments in atopic dermatitis"],"prefix":"10.1016","volume":"126","author":[{"given":"Neha","family":"Puar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic dermatitis","volume":"36","author":"Sacotte","year":"2018","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2020.08.016_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clindermatol.2014.12.004","article-title":"Epidemiology of childhood atopic dermatitis","volume":"33","author":"Garg","year":"2015","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.08.016_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2020.08.016_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"20","key":"10.1016\/j.anai.2020.08.016_bib5","first-page":"30498","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"S0190-9622","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2017.10.002","article-title":"Barrier dysfunction in the skin allergy","volume":"67","author":"Egawa","year":"2018","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"10.1016\/j.anai.2020.08.016_bib9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2020.08.016_bib10","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res"},{"issue":"378","key":"10.1016\/j.anai.2020.08.016_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis","volume":"9","author":"Nakatsuji","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.anai.2020.08.016_bib16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaad.2018.10.054","article-title":"A\u00a0retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor","volume":"80","author":"Pao-Ling","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.08.016_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.08.016_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaad.2016.04.001","article-title":"OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study","volume":"75","author":"Hanifin","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2020.08.016_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/1346-8138.12534","article-title":"Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial","volume":"41","author":"Furue","year":"2014","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2020.08.016_bib23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib24","doi-asserted-by":"crossref","unstructured":"Papp K, Szepietowski JC, Kircik L, et\u00a0al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase III randomized double-blind studies. Paper presented at: 2nd Annual Revolutionizing Atopic Dermatitis Conference. April 5, 2020; Chicago, Illinois.","DOI":"10.25251\/skin.4.supp.95"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib26","article-title":"Safety of ATI-502, a novel topical JAK1\/3 inhibitor, in adults with moderate to severe atopic dermatitis (AD): results from phase 2a, open-label trial. Paper presented at: American Academy of Dermatology Virtual Meeting Experience (AAD VMX)","volume":"13","author":"Smith","year":"2020","journal-title":"June"},{"issue":"10","key":"10.1016\/j.anai.2020.08.016_bib27","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"20","key":"10.1016\/j.anai.2020.08.016_bib28","first-page":"31011","article-title":"Efficacy and patient-reported outcomes from a phase IIb, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"S0190-9622","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib29","author":"Niemeyer-van der Kolk"},{"issue":"3","key":"10.1016\/j.anai.2020.08.016_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.anai.2018.12.003","article-title":"The role of the skin microbiome in atopic dermatitis","volume":"122","author":"Nakatsuji","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.anai.2020.08.016_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120608","article-title":"First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis","volume":"3","author":"Myles","year":"2018","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.anai.2020.08.016_bib32","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10086","key":"10.1016\/j.anai.2020.08.016_bib33","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, Phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib35","author":"Paller"},{"key":"10.1016\/j.anai.2020.08.016_bib36","article-title":"A\u00a0phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","author":"Paller","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2020.08.016_bib37","author":"de Wijs"},{"issue":"10","key":"10.1016\/j.anai.2020.08.016_bib38","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib40","doi-asserted-by":"crossref","unstructured":"Simpson E, Blauvelt A, Guttman-Yassky E, et\u00a0al. Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: results from two 52-week phase 3 trials (ECZTRA 1 and ECZTRA 2). Paper presented at: the American Academy of Dermatology Virtual Meeting Experience (AAD VMX). June 12,\u00a02020.","DOI":"10.25251\/skin.4.supp.96"},{"key":"10.1016\/j.anai.2020.08.016_bib41","unstructured":"Silverberg J. Efficacy and safety of tralokinumab with concomitant topical corticosteroids in adult patients with moderate to severe atopic dermatitis: results from the 32 week phase III ECZTRA 3 trial. Paper presented at: the American Academy of Dermatology Virtual Meeting Experience (AAD VMX). June 12,\u00a02020."},{"issue":"9","key":"10.1016\/j.anai.2020.08.016_bib42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.08.016_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2020.08.016_bib45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib48","author":"Ungar"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2020.08.016_bib50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.anai.2020.08.016_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2020.08.016_bib52","unstructured":"Simpson E, Forman S, Silverberg J, et\u00a0al. efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5) [Abstract]. Br J Dermatol. Presented at the 2nd Annual Revolutionizing Atopic Dermatitis Conference. April 5, 2020. Chicago, Illinois."},{"issue":"3","key":"10.1016\/j.anai.2020.08.016_bib53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2020.08.016_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2020.08.016_bib56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib57","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib58","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.08.016_bib59","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bjd.17455","article-title":"Efficacy and safety of PAC-14028 cream\u2014a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial","volume":"180","author":"Lee","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2020.08.016_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100610","article-title":"A\u00a0randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers","volume":"9","author":"Gibson","year":"2014","journal-title":"PLoS One"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062030572X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062030572X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T15:31:23Z","timestamp":1731166283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062030572X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S108112062030572X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.08.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}